Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)

SHE:002589 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	4,984	5,061	5,340	4,579	5,753
Trading Asset Securities	-	-	-	-	40.79
Cash & Short-Term Investments	4,984	5,061	5,340	4,579	5,794
Cash Growth	-1.52%	-5.23%	16.63%	-20.97%	13.77%
Accounts Receivable	4,375	4,222	4,603	11,276	15,183
Other Receivables	892.75	990.01	1,670	1,897	1,429
Receivables	5,268	5,212	6,274	13,172	16,611
Inventory	734.74	1,119	954.51	2,068	2,938
Prepaid Expenses	-	0.34	-	7.27	0.9
Other Current Assets	94.88	146.84	250.97	845.88	1,217
Total Current Assets	11,081	11,539	12,820	20,672	26,561
Property, Plant & Equipment	2,238	2,277	2,297	2,527	3,189
Long-Term Investments	746.72	852.03	594.07	805.82	777.68
Goodwill	146.67	146.67	146.69	620.27	804.51
Other Intangible Assets	440.89	552.39	624.21	478.35	319.63
Long-Term Accounts Receivable	-	-	-	0.07	0.87
Long-Term Deferred Tax Assets	286.15	284.44	106.68	122.86	92.43
Long-Term Deferred Charges	39.16	60.87	89.93	134.58	148.71
Other Long-Term Assets	1,033	996.39	1,654	1,035	243.91
Total Assets	16,012	16,709	18,332	26,397	32,137
Accounts Payable	3,382	3,723	7,715	9,791	8,274
Accrued Expenses	19.15	66.98	57.68	227.5	472.3
Short-Term Debt	6,092	6,651	3,926	4,440	10,055
Current Portion of Long-Term Debt	156.14	5.6	6.51	6.3	-
Current Portion of Leases	-	0.52	1.82	10.09	1.2
Current Income Taxes Payable	26.25	1.68	5	91.82	154.62
Current Unearned Revenue	14.03	29.12	32.43	174.72	233.92
Other Current Liabilities	243.79	283.63	724.46	1,766	1,977
Total Current Liabilities	9,933	10,761	12,468	16,508	21,168
Long-Term Debt	327.08	261.27	67.2	48.5	8.36
Long-Term Leases	4.12	0.84	2.73	39.19	-
Long-Term Unearned Revenue	4.74	1.62	1.93	17.5	18.88
Long-Term Deferred Tax Liabilities	48.5	47.48	40.58	83.56	181.34
Other Long-Term Liabilities	-	-	-	7.28	245.62
Total Liabilities	10,318	11,072	12,581	16,704	21,622
Common Stock	1,505	1,505	1,505	1,505	1,505
Additional Paid-In Capital	3,589	3,720	3,701	4,015	4,020
Retained Earnings	444.35	453.83	432.66	2,278	2,175
Treasury Stock	-	-230.65	-230.65	-230.65	-230.65
Total Common Equity	5,538	5,448	5,407	7,567	7,469
Minority Interest	156.83	189.18	344	2,126	3,046
Shareholders' Equity	5,695	5,637	5,751	9,693	10,515
Total Liabilities & Equity	16,012	16,709	18,332	26,397	32,137
Total Debt	6,579	6,919	4,004	4,544	10,064
Net Cash (Debt)	-1,595	-1,858	1,336	34.82	-4,271
Net Cash Growth	-	-	3737.34%	-	-
Net Cash Per Share	-1.06	-1.23	0.90	0.02	-2.94
Filing Date Shares Outstanding	1,509	1,496	1,496	1,496	1,496
Total Common Shares Outstanding	1,509	1,496	1,496	1,496	1,496
Working Capital	1,148	777.98	351.12	4,164	5,393
Book Value Per Share	3.67	3.64	3.61	5.06	4.99
Tangible Book Value	4,950	4,749	4,636	6,468	6,345
Tangible Book Value Per Share	3.28	3.17	3.10	4.32	4.24
Buildings	-	1,819	1,865	1,468	1,695
Machinery	-	695.38	778.65	1,436	1,530
Construction In Progress	-	429.34	315.37	549.58	870.89

Source: S&P Global Market Intelligence. Standard template. Financial Sources.